To Determine the Safety and Immunogenicity of an Oral Whole Cell ShanChol Cholera Vaccine in Bangladesh
To Determine the Safety and Immunogenicity of an Oral Whole Cell ShanChol Cholera Vaccine in Bangladesh
Background: Severe dehydrating cholera due to V. cholerae O1 is an important public health
 problem in Bangladesh and many other developing countries. V. cholerae O1 is a major
 bacterial pathogen causing around 5 million cases and at least 200,000 deaths in adults and
 children each year. It can be assumed that there are at least 300,000 severe cases and 1.2
 million infections in people in Bangladesh alone. The rate of cholera varies from around 1 to
 8 per 1000 population and the highest attack rate is in children 2- to 9-year years of age .
 Cholera is now also being documented in very young children. Currently enteric vaccine
 approaches are regarded as the most accessible short term and practical means to prevent and
 control such illnesses to prevent disease and epidemics in resource poor settings with
 limited public health and sanitary facilities.

 An effective inactivated whole cell bivalent cholera vaccine against Vibrio cholerae O1 and
 O139 was produced and implemented for public health purposes in Vietnam since the 1990s. This
 bivalent vaccine has been found to be safe and to confer significant protection against El
 Tor cholera in both children and adults and has over the last decade being used in the
 Vietnam to protect against cholera. This vaccine has further been reformulated by the IVI to
 meet WHO requirements and is now being produced in WHO prequalified vaccine company in India.

 The reformulated vaccine has been shown to be safe and immunogenic in Indian children as well
 as adults. A large Phase III study of the vaccine, has recently been carried out in Kolkata,
 India in over 120,000 participants aged from one year and above. Results of the study are
 encouraging and the vaccine gives over 60% protection against cholera. The vibriocidal
 antibody response rate was 80% in children and 53% in adults. Following this study, the
 vaccine, designated as ShanChol has been licensed in India in April 2009. The vaccine is now
 being marketed in India and is available at a cost affordable for developing country
 settings.

 Objective: The aim of the proposed study is to assess if the orally administered, killed,
 bivalent whole-cell cholera vaccine, ShanChol will be safe and immunogenic in different age
 groups in Bangladesh in children and adults.

 Study design: This will be a randomized, double blind, placebo-controlled study on a total of
 330 subjects, 165 vaccine and 165 placebo recipients. The specific aims will be to determine:
 i) safety and determine adverse events if any (ii) determine immune responses.

 Relevance: The study of ShanChol on Bangladeshi children and adults will be able to give
 information regarding the safety and immunogenicity of the vaccine in Bangladeshi subjects.
 This information will be important for proceeding with larger studies in Bangladesh and if
 proven useful for introduction the cholera vaccine in the country in the future.
Adults as well as children, both males and females will be recruited in the study from the
 urban suburbs around Dhaka city in Mirpur where we have been conducting other epidemiological
 and vaccine related studies. The community will be informed by our field staffs and
 interested persons might be enrolled in the study on the basis of inclusion/exclusion
 criteria.

 Part I- Adults- 18-45 years of age (n=110):

 Since this oral bivalent whole-cell cholera vaccine has not been tested in Bangladesh before,
 the study will be carried out in 3 age groups, i.e. adults, followed by toddlers and younger
 children. These study participants will be recruited from the field site in Mirpur. For this
 purpose, 55 adults (18-45 year old) will be given 2 doses of the bivalent whole-cell cholera
 vaccine and 55 adults will be given placebo. Safety will be clinically monitored for side
 effects for 3 days after each dose of study agent by home visits. Participants will be
 randomized to receive either 2 doses of the vaccine or placebo, given 14 days apart.

 Part II- Children 2-5 years (n=110):

 If the vaccine is found safe in the adult study, it will be tested in the toddlers in the
 field consisting of 55 children in each group. The children will be clinically monitored for
 side effects for 3 days after each dose of vaccine.

 Part III- Children 12-23 months (n=110):

 Children in the field site will be recruited for the study and study carried out as described
 above.

 Study procedure:

 Each phase of the study (Part I onwards) will be completed and based on the development, and
 progress, the next phase will be initiated. If the vaccine is found to be without adverse
 effects on the adults it will be tested in the children, 2-5 years of age and followed by the
 younger age group 12-23 months of age. The results will be presented to the Data Safety
 Monitoring Board after completing the safety surveillance part of each phase of the study and
 before proceeding to the next study group.

 Surveillance for side effects:

 The safety of the study agents will be monitored after the intervention has been initiated.
 In the community, supervision will be carried out by the physician and the trained research
 assistants and adverse reactions including diarrhea, vomiting, nausea and other local and
 systemic reactions recorded. For the all three groups, 3 consecutive days after the each dose
 of study agent, the participants or their guardians will be interviewed for recall of
 symptoms by health workers. All side-effects will be recorded up to 28 days in reaction
 surveillance forms for local and systemic reactions. If any adverse event or serious adverse
 events notified within the study period field clinic will be available for reporting and
 possible management of the event. Reported symptoms other than appetite loss will be graded
 as mild (noticeable), moderate (affecting normal daily activities) or severe (suspending
 normal daily activities). A clinical record form will be used to record all clinical signs
 and symptoms. In case of serious adverse effects the data will be entered in a separate form
 . If required the study subject will be hospitalized at the Mirpur Treatment Center or the
 ICDDR,B Dhaka Hospital under supervision of the study physicians..

 Safety endpoint and safety evaluation:

 The primary end point for evaluating safety will be defined as the occurrence of any of the
 following diarrhoea, vomiting or abdominal cramps of at least moderate grade. Diarrhea will
 be defined as three or more loose or liquid stools in any 24-h period over the 3 day
 surveillance period.

 STUDY INTERVENTION Vaccine Each dose of the vaccine contains whole cell inactivated heat
 killed and formalin killed bacteria consisting of 600 ELISA Units (EU) of lipopolysaccharide
 (LPS). It consists of formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973).
 It also contains 300 EU LPS of heat-killed V. cholerae Ogawa classical biotype (Cairo 50);
 300 EU LPS of formalin killed V. cholerae Ogawa classical biotype (Cairo 50); 300 EU LPS of
 heat-killed V. cholerae Inaba, classical biotype (Cairo 48); and 600 EU LPS of formalin
 killed V. cholerae O139 (4260B) (9). The vaccine has no detectable cholera toxin. The study
 agents (Vaccine or placebo) is packaged as liquid formulations in 1.5-ml doses. The vaccine
 will be given in two doses separated by a two week interval and administered by oral syringe
 without a needle after which each participant will be offered water. No buffer will be co
 administered.

 Placebo The placebo consists of heat-killed Escherichia coli K12 and is identical in
 appearance to the vaccine. This strain has been used for placebo related studies in previous
 oral vaccine clinical trials in Bangladesh and elsewhere.

 Random Allocation Eligible participants will be assigned to receive the vaccine or placebo in
 a 1:1 ratio according to the randomization schedule. Individual randomization lists for
 adults, toddlers and infants will be generated by statistician in IVI who will not involved
 in the study in any way.

 The study agents will be labeled by different letter codes for three different phases at
 Shantha Biotechnics according to the list provided by IVI.

 The field staff will allocate the study agents to the participants according to the next
 available number on entry into the trial which will be linked with the randomization list
 provided by IVI.

 The randomization list will contain sequential numbers unique to each participant, and the
 block randomization (fixed block length of 4) process will be employed to ensure an effective
 balance between the interventions.

 Data Safety Monitoring Board (DSMB):

 A 4-5 member data safety and monitoring board (DSMB) will be formulated for this study by the
 Ethical Review Committee (ERC) of ICDDR,B. This will be comprised of members of the ERC,
 staff members of ICDDR,B and individuals from other institutions in Bangladesh. The team will
 also comprise an International member. The members will not be involved in the study in any
 way.

 Blinding and Code Breaking Procedures Vials will be labeled by letter codes at Shanta
 Biotechnics according to the list provided by IVI. All study personnel and participants will
 be blinded to treatment assignment during the duration of the study.

 The identity of the study agent will not be known to the participant or their
 parent/guardian, nor to personnel involved in the conduct or monitoring of the trial, such as
 investigators, study nurses/personnel before the completion of the study.

 The PI will hold the sealed randomization list for use if necessary in case of adverse events
 that may be seen in the study by the DSMB. Otherwise the list will not be unblinded until
 completion of the study, and complete entry and editing of relevant data before initiation of
 the analyses. The entire data set will be locked prior to unblinding. If the intervention
 assignment is un-blinded due to any reason, the DSMB will be notified within 24 hours.

 Subject withdrawal during the study Respective participants or parents of participating
 children may discontinue his/her participation at any time after enrollment without providing
 any reason. No replacement will occur for such withdrawals.

 The following criteria should be checked at each visit subsequent to the intake of study
 agent

 1. Use of any immunosuppressive or immune-modifying drugs during the study period (for
 corticosteroids this would mean ≥0.5 mg/kg.day)

 2. Administration of immunoglobulins or any blood product during the study period If any of
 the above occurs that might compromise per protocol assessment (PP); however, they will
 not be withdrawn from the study and their data will be used in an "intention to treat"
 (ITT) analysis. The investigator(s) might also withdraw a participant if, in his/her
 clinical opinion, that is in the best interest of the participant concerned or if it is
 considered to be non-compliant with the protocol. A participant might also be withdrawn
 due to protocol violation, death or early termination of the study by the sponsor.
 Wherever possible, the tests and evaluations at termination visit, as specified in the
 protocol, will be carried out.

 Duration of the study period for individual participants The participants will remain in
 the study for up to 28 days.

 Schedule and description of observations and visits:

 The following schedule will be used in the study and the case report forms will be
 completed on each study day:

 3. Day 0: After describing the study and initial verbal consent, medical history will be
 obtained and a thorough physical examination will be performed by a physician that will
 include measurement of the vitals signs. Once all eligibility criteria are met,the
 participant and in case of children the parent will be asked to sign the informed
 consent form. A blood and stool sample would be collected for determining the baseline
 immunological assay for immune responses. Following this, the participant will be
 allocated to the study intervention according to the randomization list (vaccine or
 placebo). Voluntary and solicited reactogenicity will be assessed symptoms and immediate
 adverse events recorded with 1 h of intake of the study agent. The participants will
 then be allowed to go home

 4. Day 1: Participants return to the study center to be monitored for voluntary and
 solicited symptoms and adverse events.

 5. Day 2: Participants will return to the study centre or will be visited at home (in
 exceptional circumstances, when parents cannot bring the participant to the study
 centre) to monitor for voluntary and solicited symptoms and adverse events.

 6. Day 7: (up to +3 days): Participants return to the study center. Blood sample will be
 collected at clinic and stool sample will be collected from home or at clinic for
 testing of vaccine specific immunologic responses in study participants.

 7. Day 14: (± 2 days): Participants return to the study center. The participant will be
 allocated to the study intervention for second time according to the randomization list
 (vaccine or placebo).by a blinded third party dispenser.

 8. Day 14-16: Participants return to the study centre or will be visited at home (in
 exceptional circumstances, when parents cannot bring the participant to the study
 centre) to monitor for voluntary and solicited symptoms and adverse events. Voluntary
 and solicited reactogenicity will be assessed symptoms and immediate adverse events.

 9. Day 21: (± 3 days) Blood and stool will be sampled for testing of vaccine specific post
 immunization response.

 10. Day 28: (± 3 days) Clinical evaluation and Study Termination Sample Size Calculation and
 Outcome (Primary and Secondary) Variable(s) Safety and Immunogenicity study of the
 Shantha cholera vaccine: The ''non-inferiority'' approach using a 1 -sided 95%
 confidence interval was used to calculate the sample size since this allowed us to rule
 out clinically unacceptable high rates of diarrheal adverse event occurring during the 3
 days after either dose as well as establish that the vaccine induced adequate
 seroconversion to V. cholerae O1 among recipients. Assuming a 10% diarrheal rate among
 placebo and vaccine recipients alike, to exclude a vaccine-placebo difference in the
 rate of diarrhea of greater than 20% (upper boundary of the 1-tailed 95% confidence
 interval) with a power of 0.9, the minimum number of subjects required for each group
 was in each group for both adverse event was 46. The sample size is calculated with the
 assumptions that it is important to evaluate whether the vaccine induces acceptable
 serum vibriocidal responses in relation to the placebo group. Based on an immunogenicity
 study of the whole-cell killed oral cholera vaccine in Bangladesh, we make the following
 assumptions. For serum vibriocidal responses, defined as >4-fold increases between
 baseline and post-second dose in either Inaba or Ogawa antibodies, for each age group
 (12-23 months, 2-5 years and 18-45 years), we assume 1) the background rate of responses
 in the placebo group will be 5% after the second dose and 2) the true rate of
 vibriocidal responses in the vaccine groups is 25%. At p <0.05 (1-tailed), 0.8 power,
 and a 1 to 1 allocation of vaccine and placebo, a total of 46 subjects per group would
 be needed. Thus for safety and immunological responses the number is 46 per group. With
 15% attrition rate, it is 53. We will select 55 in each group (110 per age group for
 both vaccine and placebo recipient).

 We will, therefore, select 55 subjects per arm in each age group, with a total of 330
 subjects.
Inclusion Criteria:

 1. Age: 12-23 months for younger children group, 2-5 years for the toddler group and
 18-45 years for the adult group.

 2. Sex: Either

 3. Consent: Written informed consent from study participants and parents in case of
 children.

 4. Compliance to study procedures: e.g. available for follow-up visits and agrees to
 specimen collection.

 5. Apparently healthy: as determined by medical history, physical examination findings,
 and clinical judgment of the study physician.

 Exclusion Criteria:

 1. Chronic disease: history or evidence of chronic illness.

 2. Gastrointestinal symptoms such as abdominal pain or cramps, loss of appetite, nausea,
 general ill-feeling or vomiting in the past 24 hours or abdominal pain lasting for
 more than 2 weeks in the past 6 months

 3. Intake of any anti-diarrheal medicine or antimicrobial therapy the past week.

 4. Acute disease one week prior to enrollment, with or without fever ≥38ºC .

 5. Receiving of cholera vaccine any time in the past, and any other live or killed
 enteric vaccine in the last 4 weeks.

 6. Diarrhea within 6 week period at screening.